Laboratory evaluation of the Coasys® Plus C coagulation analyzer

Bie, Prim de; Schornagel, Willem J.; Dool, Erik-Jan van den; Bakker, B. H.; Dam, Willem van; Heckman, Marion; Ağar, C.; Sturk, Auguste; Stroobants, An K.

doi:10.1016/j.thromres.2013.02.004

Cited by 3 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Laboratory tests were drawn on the floor and processed by our institution's clinical laboratory, which is Clinical Laboratory Improvement Amendments (CLIA) certified, accredited by the College of American Pathologists, and licensed by the state of Tennessee. Fibrinogen was tested in accordance with the Clauss clotting method using the STA-R Evolution Analyzer with reagents from Diagnostica Stago, Inc. Interassay coefficients of variation have been reported to range from 3.0% to 4.8% [20]. CRP levels were measured using an immunoturbidimetric assay with the Architect C1600 by Abbott Laboratories with reported interassay coefficients of variation of 0.44% to 1.25% [21].…”

Section: Laboratory Methodsmentioning

confidence: 99%

Characterizing the Acute Phase Response in Healthy Patients Following Total Joint Arthroplasty: Predictable and Consistent

Oelsner

Engstrom

Benvenuti

et al. 2017

The Journal of Arthroplasty

View full text Add to dashboard Cite

show abstract

Section: Laboratory Methodsmentioning

confidence: 99%

Characterizing the Acute Phase Response in Healthy Patients Following Total Joint Arthroplasty: Predictable and Consistent

Oelsner

Engstrom

Benvenuti

et al. 2017

The Journal of Arthroplasty

View full text Add to dashboard Cite

show abstract

“…The highest reported volume requirement for a single run was 600 lL of plasma (~1.5 mL whole blood) from the laboratory using the Coasys Plus C. However, this requirement was likely related to a laboratory-specific procedure, as volume requirements for a single assay run for the Coasys Plus C analyzer have been reported to be 27-90 lL plasma/assay, similar to those described for other coagulation analyzers. 8,9 Considerations on small bench-top automated analyzers…”

Section: Clinical Biochemistrymentioning

confidence: 99%

Reducing blood volume requirements for clinical pathology testing in toxicologic studies—points to consider

Poitout-Belissent

Aulbach

Tripathi

et al. 2016

Veterinary Clinical Pathol

View full text Add to dashboard Cite

In preclinical safety assessment, blood volume requirements for various endpoints pose a major challenge. The goal of this working group was to review current practices for clinical pathology (CP) testing in preclinical toxicologic studies, and to discuss advantages and disadvantages of methods for reducing blood volume requirements. An industry-wide survey was conducted to gather information on CP instrumentation and blood collection practices for hematology, clinical biochemistry, and coagulation evaluation in laboratory animals involved in preclinical studies. Based on the survey results and collective experience of the authors, the working group proposes the following "points to consider" for CP testing: (1) For most commercial analyzers, 0.5 mL and 0.8 mL of whole blood are sufficient for hematology and biochemistry evaluation, respectively. (2) Small analyzers with low volume requirements and low throughput have limited utility in preclinical studies. (3) Sample pooling or dilution is inappropriate for many CP methods. (4) Appropriate collection sites should be determined based on blood volume requirements and technical expertise. (5) Microsampling does not provide sufficient volume given current analyzer and quality assurance requirements. (6) Study design considerations include: the use of older/larger animals (rodents), collection of CP samples before toxicokinetic samples, use of separate subsets of mice for hematology and clinical biochemistry testing, use of a priority list for clinical biochemistry, and when possible, eliminating coagulation testing.

show abstract

Evaluating the analytical performance of four new coagulation assays for the measurement of fibrinogen, D‐dimer and thrombin time

Kitchen¹,

Geisen

Kappelmayer

et al. 2018

Int J Lab Hematology

View full text Add to dashboard Cite

show abstract

Laboratory evaluation of the Coasys® Plus C coagulation analyzer

Cited by 3 publications

References 7 publications

Characterizing the Acute Phase Response in Healthy Patients Following Total Joint Arthroplasty: Predictable and Consistent

Characterizing the Acute Phase Response in Healthy Patients Following Total Joint Arthroplasty: Predictable and Consistent

Reducing blood volume requirements for clinical pathology testing in toxicologic studies—points to consider

Evaluating the analytical performance of four new coagulation assays for the measurement of fibrinogen, D‐dimer and thrombin time

Contact Info

Product

Resources

About